



## Supernus to Present at Two September Healthcare Conferences

August 26, 2019

ROCKVILLE, Md., Aug. 26, 2019 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that the Company's management will present a Company overview and update, as well as host investor meetings, at the following September conferences:

### Wells Fargo 2019 Healthcare Conference

Date: Thursday, September 5, 2019  
Time: 1:20 p.m. ET  
Place: The Westin Copley Place, Boston, MA

### Morgan Stanley 2019 Global Healthcare Conference

Date: Wednesday, September 11, 2019  
Time: 11:05 a.m. ET  
Place: Grand Hyatt New York in New York City

Investors interested in arranging a meeting with the Company's management during these conferences should contact the respective conference coordinator.

A live webcast of the presentations can be accessed by visiting 'Events & Presentations' in the Investor Relations section on the Company's website at [www.supernus.com](http://www.supernus.com). An archived replay of these webcasts will be available for 60 days on the Company's website after the conference.

### About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company currently markets Trokendi XR® (extended-release topiramate) for the prophylaxis of migraine and the treatment of epilepsy, and Oxtellar XR® (extended-release oxcarbazepine) for the treatment of epilepsy. The Company is also developing several product candidates to address large market opportunities in the CNS market, including SPN-810 for the treatment of Impulsive Aggression in ADHD patients, SPN-812 for the treatment of ADHD, and SPN-604 for the treatment of bipolar disorder.

### CONTACT:

Jack A. Khattar, President and CEO  
Gregory S. Patrick, Senior Vice President and CFO  
Supernus Pharmaceuticals, Inc.  
Tel: (301) 838-2591

Or

Investor Contact:  
Peter Vozzo  
Westwicke  
Office: (443) 213-0505  
Mobile: (443) 377-4767  
Email: [peter.vozzo@westwicke.com](mailto:peter.vozzo@westwicke.com)



Source: Supernus Pharmaceuticals, Inc.